{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T21:35:46Z","timestamp":1788039346590,"version":"build-2784847793"},"reference-count":12,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T00:00:00Z","timestamp":1434412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.clinthera.2015.05.498","type":"journal-article","created":{"date-parts":[[2015,6,20]],"date-time":"2015-06-20T05:48:10Z","timestamp":1434779290000},"page":"1555-1563","source":"Crossref","is-referenced-by-count":10,"title":["Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults"],"prefix":"10.1016","volume":"37","clinical-trial-number":[{"clinical-trial-number":"2011-000596-13","registry":"10.18810\/euctr"}],"author":[{"given":"Peter E.","family":"Haroldsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald G.","family":"Musson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyd","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Quartel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.05.498_bib1","first-page":"973808","article-title":"Lambert-Eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy","volume":"2011","author":"Gilhus","year":"2011","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.clinthera.2015.05.498_bib2","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1185\/03007991003745209","article-title":"Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment","volume":"26","author":"Quartel","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2015.05.498_bib3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2015.05.498_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1212\/01.WNL.0000078893.41040.56","article-title":"Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study","volume":"61","author":"Strupp","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2015.05.498_bib5","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/088307389601100608","article-title":"3,4-diaminopyridine in childhood myasthenia: double-blind, placebo-controlled trial","volume":"11","author":"Anlar","year":"1996","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clinthera.2015.05.498_bib6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0006-8993(84)90875-8","article-title":"Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats","volume":"304","author":"Lemeignan","year":"1984","journal-title":"Brain Res"},{"key":"10.1016\/j.clinthera.2015.05.498_bib7","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","article-title":"3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome","volume":"321","author":"McEvoy","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.05.498_bib8","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1196\/annals.1254.065","article-title":"Lambert-Eaton myasthenic syndrome: diagnosis and treatment","volume":"998","author":"Sanders","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinthera.2015.05.498_bib9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1468-1331.2006.01476.x","article-title":"Guidelines for the treatment of autoimmune neuromuscular transmission disorders","volume":"13","author":"Skeie","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2015.05.498_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2710.2011.01249.x","article-title":"Content variability of active drug substance in compounded oral 3,4-diaminopyridine products","volume":"37","author":"Green","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2015.05.498_bib11","unstructured":"Firdapse (amifampridine) [European Medicines Agency Summary of Product Characteristics]. London: BioMarin Europe Ltd; 2010."},{"issue":"1","key":"10.1016\/j.clinthera.2015.05.498_bib12","doi-asserted-by":"crossref","first-page":"e00099","DOI":"10.1002\/prp2.99","article-title":"Genetic variation of aryl n-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate","volume":"3","author":"Haroldsen","year":"2015","journal-title":"Pharmacol Res Perspect"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815008310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815008310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T12:22:45Z","timestamp":1537532565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815008310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0149291815008310"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.05.498","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}